Lenalidomide Sandoz 25 Mg Hard Capsules (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the ligase’s substrate specificity, leading to the ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. The resulting anti‑proliferative, anti‑angiogenic, and immunomodulatory actions suppress malignant cell growth and modify the tumor microenvironment.

The dosing regimen for lenalidomide is individualized and determined by the prescribing clinician based on the specific indication, disease stage, renal function, and patient tolerance. Physicians may start with a dose ranging from 10 mg to 25 mg taken orally once daily on a schedule that aligns with treatment protocols, but the exact regimen should always follow the prescriber’s order.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended, as the drug may be excreted in milk and could affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenalidomide Sandoz 25 mg hard capsules. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any required temperature control), and assists with import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug (IMiD) class, but lenalidomide is more potent and has a different safety profile. Lenalidomide generally shows higher response rates in multiple myeloma and a lower incidence of peripheral neuropathy compared with thalidomide, while still carrying risks such as thrombosis and neutropenia. Choice of therapy depends on individual patient factors and physician judgment.

Lenalidomide Sandoz 25 mg hard capsules should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the capsules in the original blister pack or container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

The medication is administered orally. Patients should swallow the hard capsule whole with a glass of water, preferably on an empty stomach or as directed by the prescriber. Dosing schedules (e.g., daily or on specific days of a cycle) are defined by the treating physician based on the therapeutic indication and patient tolerance.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to life‑threatening infections, and the potential development of secondary primary malignancies. Patients should be monitored regularly for signs of clotting, infection, and any new cancerous lesions, and should report concerning symptoms promptly to their healthcare provider.

Lenalidomide should not be used by individuals who are pregnant or breastfeeding, those with known hypersensitivity to lenalidomide or any component of the formulation, and patients with uncontrolled active infections. Caution is also advised for patients with severe renal or hepatic impairment, and those with a history of thromboembolic disease unless appropriate prophylaxis is in place.